Shuwen Biotech Wins at the 7th Annual China Innovation and Entrepreneurship Competition
Deqing, China, December 07, 2018 / B3C newswire / -- Shuwen Biotech announces its winning of an outstanding award in the national finals for the 7th Annual Innovation and Entrepreneurship organized by Chinese Ministry of Science and Technology held on November 14. The 230 national finalists were selected from 3,667 biomedical enterprises from all across China through local and provincial competitions. Shuwen Biotech, with its proprietary CapCord™ Preeclampsia Detection Kit, entered the national finals with the First Place Award in the city of Xuancheng and the First Place Award in biotechnology of Anhui Province.
Shuwen developed the CapCord™ Preeclampsia Detection Kit under a patent licensing and collaboration between Shuwen Biotech and Yale University. The non-invasive point of care test (POCT) is used in the prediction, screening, and diagnosis of preeclampsia and shows an accuracy rate of 95%. Preeclampsia affects about 2.5-7% of all pregnant women and is the second leading cause of death among pregnant women all over the world. Shuwen’s CapCord™ Preeclampsia Detection Kit uses a non-invasive urine detection method, which is quick, effective, and shows results in 3 minutes. The product is protected by patents in many countries covering novel biomarkers, detection methods, and diagnostic devices. Shuwen Biotech expects to begin sales in the coming months.
The recognition in the competition highlights Shuwen’s outstanding ability to develop and commercialize innovative first-in-class diagnostic products.
About Shuwen Biotech
Shuwen Biotech is a China-based diagnostic company founded on the principles of innovation, patent protection, and international collaboration as its strategic platforms for growth. Since 2011, Shuwen established strategic partnerships with numerous outstanding academic and commercial institutions such as Yale University, University of Chicago, BioNTech, Sphingotec among others in the form of exclusive licensing of first-in-class diagnostic technologies and patents covering a range of novel biomarkers for companion diagnostics and other diagnostics in the fields of cancer, women’s health, critical care, and health screening and other fields. Shuwen has also developed innovative and quality companion diagnostics and provided central lab testing services to leading pharmaceutical developers. Shuwen houses an in-house development team, CAP-accredited central labs, and ISO13485-certified IVD manufacturing facilities, all in line with global standards in order to continue to deliver transformational products and services to its customers globally and open new possibilities in the advancement of health.